SCHEMBL20119679

SCHEMBL20119679

Cc1c[nH]c2ncnc(NCc3ccco3)c12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 11/20 0.58
TSHR P16473 6/20 0.58
ALDH1A1 P00352 6/20 0.58
MAPK1 P28482 5/20 0.58
MAPT P10636 5/20 0.58
POLB P06746 4/20 0.58
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
ALOX15 P16050 2/20 0.58
TDP1 Q9NUW8 2/20 0.58
ESR1 P03372 1/20 0.58
ESR2 Q92731 1/20 0.58
HIF1A Q16665 2/20 0.55
CYP1A2 P05177 2/20 0.55
TP53 P04637 1/20 0.55
ADORA3 P0DMS8 1/20 0.55
KDR P35968 1/20 0.55
HTT P42858 7/20 0.51
RAB9A P51151 2/20 0.51
REN P00797 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119639 0.81 CDC7 (0.60) SMN1; SMN2TSHRALDH1A1MAPK1MAPT
SCHEMBL29377513 0.81 CDC7 (0.60) SMN1; SMN2TSHRALDH1A1MAPK1MAPT
SCHEMBL20120006 0.80 SMN1; SMN2 (0.56) SMN1; SMN2TSHRALDH1A1MAPK1MAPT
SCHEMBL20119672 0.80 SMN1; SMN2 (0.50) SMN1; SMN2TSHRALDH1A1MAPK1MAPT
Kinetin SCHEMBL15705 0.75 SMN1; SMN2 (0.66) SMN1; SMN2TSHRALDH1A1MAPK1MAPT
SCHEMBL20119913 0.75 POLB (0.66) SMN1; SMN2TSHRALDH1A1MAPK1MAPT
Kinetin SCHEMBL29829493 0.75 SMN1; SMN2 (0.66) SMN1; SMN2TSHRALDH1A1MAPK1MAPT
SCHEMBL2467960 0.75 KMT2A (0.67) SMN1; SMN2TSHRALDH1A1MAPK1MAPT
SCHEMBL17009464 0.74 CCNB2 (0.56) SMN1; SMN2TSHRALDH1A1MAPK1MAPT
Hydrochloric Acid SCHEMBL22346221 0.74 POLB (0.64) SMN1; SMN2TSHRALDH1A1MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885TSHR 4371/4885ALDH1A1 2393/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885TSHR 4371/4885ALDH1A1 2393/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885TSHR 4371/4885ALDH1A1 2393/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885TSHR 4371/4885ALDH1A1 2393/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885TSHR 4371/4885ALDH1A1 2393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.